You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
Moodys
McKinsey
Mallinckrodt

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,827,963

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,827,963 protect, and when does it expire?

Patent 8,827,963 protects BYDUREON PEN and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 8,827,963
Title:Administering device with holding mechanism
Abstract: An apparatus for administering a substance, e.g. a medicinal, pharmaceutical, or cosmetic substance, includes a driving member movably mounted within the apparatus to administer the substance, and the driving member includes a holding feature or components of a holding feature which holds or retains at least one additional element of the apparatus in a position relative to the apparatus. In some embodiments, the additional element is a carpule or ampoule containing the substance, and the holding feature retains the carpule or ampoule in a position within a carpule or ampoule holder.
Inventor(s): Hirschel; Juerg (Aarau, CH), Kaenel-Jost; Celine (Zurich, CH), Moser; Ulrich (Heimiswil, CH), Tschirren; Markus (Kirchberg, CH)
Assignee: TecPharma Licensing AG (Burgdorf, CH)
Application Number:12/853,713
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 8,827,963

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,827,963

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland0188/08Feb 11, 2008

International Family Members for US Patent 8,827,963

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101998870   Start Trial
European Patent Office 2252351   Start Trial
Poland 2252351   Start Trial
World Intellectual Property Organization (WIPO) 2009100549   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
AstraZeneca
Harvard Business School
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.